




1. What is Lilly saying about  
Amyloid Plaques on current Fox News Ads?



See [www.amyloid.com](http://www.amyloid.com)

2. What and when did Anthony Fauci know about  
the SARS-CoV-2 virus?

See page 2 below or [link pg 2286](#).

3. What did medical studies show in the "Is SARS-CoV-2  
Virus Spike Protein Architecture a BioWeapon" [Poster](#)  
delivered to Senate HHSC on March 10, 2021?

Study #3 03/24/21, "SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration"

Study #4\* 01/15/21, "Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice." SARS-CoV-2 virus kills mice from spongiform encephalopathy in 14 days = 1.5 human yrs. \* Boston University School of Medicine

Study #5 02/23/21, "SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques (monkeys)."

4. What does the Lancet Medical Report say about  
Neurological Conditions from 1990-2021?

The Lancet  
Neurology:  
Neurological  
conditions now  
leading cause of ill  
health and disability  
globally, affecting  
3.4 billion people  
worldwide

Published March 14, 2024

5. What did Pfizer know about Amyloid Plaques?

See 1291 [COVID-19 "Adverse Events of SPECIAL INTEREST"](#) on pg 30 that Pfizer knew about on February 28, 2021, see page 2 below.

6. Could such a world-wide impact on  
neurological conditions be associated with  
Amyloid Plaques? Or is it Immune Paralysis? See [VAIDS](#).



p. 2286

From: (b) (6)  
Sent: Wed, 11 Mar 2020 06:19:13 -0400  
To: NIAID Public Inquiries  
Subject: Fwd: Coronavirus bioweapon production method

Sent from my iPhone

Begin forwarded message:

From: Adam Gaertner (b) (6)  
Date: March 11, 2020 at 6:16:40 AM EDT  
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >  
Subject: Coronavirus bioweapon production method

Hello Anthony,

This is how the virus was created.

Intervirion Fusion. HIV-luc(ACE2) (500 ng of p24) was mixed with 1,000 ng of p24 of HIV-gfp particles incorporating ASLV-A envelope, SARS-CoV S protein, or both envelopes in PBS at 4°C for 30 min to allow binding. Samples were raised to 37°C for 15 min to allow for conformational rearrangements. Virions were adjusted to the desired pH with 0.1 M citric acid. PBS, TPCK-trypsin (final concentration 10 µg/ml), CTSL, cathepsin B (CTSB) (final concentrations 2 µg/ml) or CTSL buffer alone was then added. Recombinant CTSL (R & D Systems) was preactivated by incubation for 15 min at 10 µg/ml in 50 mM Mes, pH 6.0, on ice. Recombinant CTSB (R & D Systems) was preactivated in 25 mM Mes, 5 mM DTT, pH 5.0, for 30 min at 25°C. After a 10-min incubation at 25°C, proteolysis was halted by the addition of 300 µl of DMEM10 containing leupeptin (25 µg/ml) and STI (75 µg/ml).

### BNT162b2 5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

as of February 28, 2021 - Note: 1p36 genetic deletion syndrome associate with intellectual disability.

#### APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

1p36 deletion syndrome; 2-Hydroxyglutaric aciduria; 5'nucleotidase increased; Acoustic neuritis; Acquired CI inhibitor deficiency; Acquired epidermolysis bullosa; Acquired epileptic

4/14 embolism; Capillaritis; Caplan's syndrome; Cardiac amyloidosis; Cardiac arrest; Cardiac failure; Cardiac failure acute; Cardiac sarcoidosis; Cardiac ventricular thrombosis; Cardiogenic embolism; Central nervous system lupus; Central nervous system vasculitis; Cerebellar artery thrombosis; Cerebellar embolism; Cerebral amyloid angiopathy; Cerebral arteritis; Cerebral artery embolism; Cerebral artery thrombosis; Cerebral gas embolism; Cerebral  
5/14 thrombosis; Pruritus; Pruritus allergic; Pseudovasculitis; Psoriasis; Psoriatic arthropathy; Pulmonary amyloidosis; Pulmonary artery thrombosis; Pulmonary  
11/14 embolism; Pulmonary fibrosis; Pulmonary haemorrhage; Pulmonary microemboli; Pulmonary